CPSF3 emerges as new synthetic lethality target in AML and sarcoma
NIBR identifies CPSF3 as novel synthetic lethality target in subsets of AML, sarcoma
A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas.
The premise of synthetic lethality is that genomic or pharmacologically induced defects that are tolerated individually become lethal when combined. The prime example is PARP inhibition,